439 related articles for article (PubMed ID: 1696296)
1. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
Bessen D; Fischetti VA
J Immunol; 1990 Aug; 145(4):1251-6. PubMed ID: 1696296
[TBL] [Abstract][Full Text] [Related]
2. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
Bronze MS; Courtney HS; Dale JB
J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
[TBL] [Abstract][Full Text] [Related]
3. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
[TBL] [Abstract][Full Text] [Related]
4. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.
Bessen D; Fischetti VA
Infect Immun; 1988 Oct; 56(10):2666-72. PubMed ID: 2458320
[TBL] [Abstract][Full Text] [Related]
5. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin.
Vashishtha A; Fischetti VA
J Immunol; 1993 May; 150(10):4693-701. PubMed ID: 8482854
[TBL] [Abstract][Full Text] [Related]
6. Recombinant tetravalent group A streptococcal M protein vaccine.
Dale JB; Chiang EY; Lederer JW
J Immunol; 1993 Aug; 151(4):2188-94. PubMed ID: 8345202
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
8. Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein.
Kraus W; Haanes-Fritz E; Cleary PP; Seyer JM; Dale JB; Beachey EH
J Immunol; 1987 Nov; 139(9):3084-90. PubMed ID: 2444650
[TBL] [Abstract][Full Text] [Related]
9. Mapping a conserved conformational epitope from the M protein of group A streptococci.
Relf WA; Cooper J; Brandt ER; Hayman WA; Anders RF; Pruksakorn S; Currie B; Saul A; Good MF
Pept Res; 1996; 9(1):12-20. PubMed ID: 8727479
[TBL] [Abstract][Full Text] [Related]
10. Conserved T and B cell epitopes on the M protein of group A streptococci. Induction of bactericidal antibodies.
Pruksakorn S; Galbraith A; Houghten RA; Good MF
J Immunol; 1992 Oct; 149(8):2729-35. PubMed ID: 1383324
[TBL] [Abstract][Full Text] [Related]
11. Protective and nonprotective epitopes of chemically synthesized peptides of the NH2-terminal region of type 6 streptococcal M protein.
Beachey EH; Seyer JM
J Immunol; 1986 Mar; 136(6):2287-92. PubMed ID: 2419429
[TBL] [Abstract][Full Text] [Related]
12. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule. Identification of an immunodominant region.
Fischetti VA; Windels M
J Immunol; 1988 Nov; 141(10):3592-9. PubMed ID: 2460540
[TBL] [Abstract][Full Text] [Related]
13. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
15. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
Mannam P; Jones KF; Geller BL
Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
[TBL] [Abstract][Full Text] [Related]
16. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain.
Bronze MS; Dale JB
J Immunol; 1993 Sep; 151(5):2820-8. PubMed ID: 7689617
[TBL] [Abstract][Full Text] [Related]
17. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
[TBL] [Abstract][Full Text] [Related]
18. Synthetic peptide fragments of streptococcal M proteins.
Seyer JM; Dale JB; Beachey EH
Dev Biol Stand; 1986; 63():101-8. PubMed ID: 2427375
[TBL] [Abstract][Full Text] [Related]
19. Processing of viable group A streptococci leads to major histocompatibility complex class II presentation of T cell epitopes from the major protective antigen.
Rossiter BA; Alfonso C; Kehoe MA; Robinson JH
Eur J Immunol; 1994 May; 24(5):1244-7. PubMed ID: 7514136
[TBL] [Abstract][Full Text] [Related]
20. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
Schulze K; Olive C; Ebensen T; Guzmán CA
Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
